I-Mab
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMAB research report →
About the company
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates.
- CEO
- Xi-Yong Fu
- IPO
- 2020
- Employees
- 32
- HQ
- Rockville, US
Price Chart
- Market Cap
- $542.01M
- P/E
- -24.64
- P/S
- 0.00
- P/B
- 22.01
- EV/EBITDA
- -52.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.59%
- ROIC
- -94.82%
- Revenue
- $0 · -100.00%
- Net Income
- $-22,222,718 · 98.48%
- EPS
- $-0.62 · 96.48%
- Op Income
- $-51,409,031
- FCF YoY
- 27.65%
- 52W High
- $6.79
- 52W Low
- $0.59
- 50D MA
- $4.44
- 200D MA
- $2.39
- Beta
- 1.46
- Avg Volume
- 1.85M
Get TickerSpark's AI analysis on IMAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IMAB coverage
Recent articles, reports, and earnings notes.
No research on IMAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMAB report →Similar companies
Peers in the same neighborhood.